Advertisement

Quality of Life 3 and 12 Months After Acute Pulmonary Embolism

Analysis From a Prospective Multicenter Cohort Study (New Hope for Outcomes Envy)
      FOR RELATED ARTICLE, SEE PAGE 2428
      We sit and stew. Stuck in our tarpit of outcomes envy. After all, those brain researchers have their Rankin Score. The endocrinologists have their hemoglobin A1c. Cardiologists have the thrombolysis in myocardial infarction flow grades, and major adverse cardiac events. Pulmonary hypertension researchers have the 6-minute walk test. But with pulmonary embolism (PE), experts entrenched in its study and treatment convene 2-day-long meetings and futilely argue over the question: what nonlethal end point can define success in the treatment of PE?
      • Sista A.K.
      • Goldhaber S.Z.
      • Vedantham S.
      • et al.
      Research priorities in submassive pulmonary embolism: proceedings from a multidisciplinary research consensus panel.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sista A.K.
        • Goldhaber S.Z.
        • Vedantham S.
        • et al.
        Research priorities in submassive pulmonary embolism: proceedings from a multidisciplinary research consensus panel.
        J Vasc Interv Radiol. 2016; 27: 787-794
        • Benotti J.R.
        • Ockene I.S.
        • Alpert J.S.
        • Dalen J.E.
        The clinical profile of unresolved pulmonary embolism.
        Chest. 1983; 84: 669-678
        • Klok F.A.
        • van der Hulle T.
        • den Exter P.L.
        • Lankeit M.
        • Huisman M.V.
        • Konstantinides S.
        The post-PE syndrome: a new concept for chronic complications of pulmonary embolism.
        Blood Rev. 2014; 28: 221-226
        • Kline J.A.
        • Steuerwald M.T.
        • Marchick M.R.
        • Hernandez-Nino J.
        • Rose G.A.
        Prospective evaluation of right ventricular function and functional status six months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure.
        Chest. 2009; 136: 1202-1210
        • Stevinson B.G.
        • Hernandez-Nino J.
        • Rose G.
        • Kline J.A.
        Echocardiographic and functional cardiopulmonary problems 6 months after first-time pulmonary embolism in previously healthy patients.
        Eur Heart J. 2007; 28: 2517-2524
        • Kahn S.R.
        • Hirsch A.M.
        • Akaberi A.
        • et al.
        Functional and exercise limitations after a first episode of pulmonary embolism: results of the ELOPE prospective cohort study.
        Chest. 2017; 151: 1058-1068
        • Kahn S.R.
        • Akaberi A.
        • Granton J.T.
        • et al.
        Quality of life, dyspnea, and functional exercise capacity following a first episode of pulmonary embolism: results of the ELOPE cohort study.
        Am J Med. 2017; 130 (990.e999-990.e921)
        • Klok F.A.
        • van Kralingen K.W.
        • van Dijk A.P.
        • et al.
        Quality of life in long-term survivors of acute pulmonary embolism.
        Chest. 2010; 138: 1432-1440
        • Stewart L.K.
        • Peitz G.W.
        • Nordenholz K.E.
        • et al.
        Contribution of fibrinolysis to the physical component summary of the SF-36 after acute submassive pulmonary embolism.
        J Thromb Thrombolysis. 2015; 40: 161-166
        • Hunter R.
        • Noble S.
        • Lewis S.
        • Bennett P.
        Long-term psychosocial impact of venous thromboembolism: a qualitative study in the community.
        BMJ Open. 2019; 9e024805
        • Etchegary H.
        • Wilson B.
        • Brehaut J.
        • Lott A.
        • Langlois N.
        • Wells P.S.
        Psychosocial aspects of venous thromboembolic disease: an exploratory study.
        Thromb Res. 2008; 122: 491-500
        • Sista A.K.
        • Miller L.E.
        • Kahn S.R.
        • Kline J.A.
        Persistent right ventricular dysfunction, functional capacity limitation, exercise intolerance, and quality of life impairment following pulmonary embolism: systematic review with meta-analysis.
        Vasc Med. 2017; 22: 37-43
        • Meyer G.
        • Vicaut E.
        • Danays T.
        • et al.
        Fibrinolysis for patients with intermediate-risk pulmonary embolism.
        N Engl J Med. 2014; 370: 1402-1411
        • Kline J.A.
        • Nordenholz K.E.
        • Courtney D.M.
        • et al.
        Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at three months (TOPCOAT): Multicenter double-blind, placebo-controlled randomized trial.
        J Thromb Haemost. 2014; 12: 549-568
        • Kline J.A.
        • Puskarich M.A.
        • Jones A.E.
        • et al.
        Inhaled nitric oxide to treat intermediate risk pulmonary embolism: a multicenter randomized controlled trial.
        Randomized Controlled Trial > Nitric Oxide. 2019; 84: 60-68
        • Valero L.
        • Barco S.
        • Jankowski M.
        • et al.
        Quality of life 3 and 12 months following acute pulmonary embolism: analysis from a prospective multicenter cohort study.
        Chest. 2021; 159: 2428-2438
        • Frump A.L.
        • Albrecht M.E.
        • Yakubov B.
        • et al.
        17β-Estradiol and estrogen receptor-α protect right ventricular function in pulmonary hypertension via BMPR2 and apelin [Published online ahead of print January 26, 2021].
        J Clin Invest. 2021; https://doi.org/10.1172/JCI129433
        • Dalton D.
        • Ortegren M.
        Gender differences in ethics research: the importance of controlling for the social desirability response bias.
        Journal of Business Ethics. 2011; 103: 73-93
        • Ladwig K.H.
        • Marten-Mittag B.
        • Formanek B.
        • Dammann G.
        Gender differences of symptom reporting and medical health care utilization in the German population.
        Eur J Epidemiol. 2000; 16: 511-518
        • Munyombwe T.
        • Hall M.
        • Dondo T.B.
        • et al.
        Quality of life trajectories in survivors of acute myocardial infarction: a national longitudinal study.
        Heart. 2020; 106: 33-39
        • Lombardo L.
        • Shaw R.
        • Sayles K.
        • Altschul D.
        Anxiety and depression in patients who undergo a cerebrovascular procedure.
        BMC Neurol. 2020; 20: 124
        • Sadlonova M.
        • Wasser K.
        • Nagel J.
        • et al.
        Health-related quality of life, anxiety and depression up to 12 months post-stroke: influence of sex, age, stroke severity and atrial fibrillation—a longitudinal subanalysis of the Find-AF(RANDOMISED) trial.
        J Psychosom Res. 2021; 142: 110353
        • Utne K.K.
        • Dahm A.
        • Wik H.S.
        • Jelsness-Jørgensen L.P.
        • Sandset P.M.
        • Ghanima W.
        Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome.
        Thromb Res. 2018; 163: 6-11
        • Kline J.A.
        • Kahler Z.P.
        • Beam D.M.
        Outpatient treatment of low risk venous thromboembolism with monotherapy oral anticoagulation: patient quality of life outcomes and clinician acceptance.
        Patient Prefer Adherence. 2016; 10: 561-569
        • Ver Hoeve E.S.
        • Ali-Akbarian L.
        • Price S.N.
        • Lothfi N.M.
        • Hamann H.A.
        Patient-reported financial toxicity, quality of life, and health behaviors in insured US cancer survivors.
        Support Care Cancer. 2021; 29: 349-358
        • Hauschildt K.E.
        • Seigworth C.
        • Kamphuis L.A.
        • et al.
        Financial toxicity after acute respiratory distress syndrome: a national qualitative cohort study.
        Crit Care Med. 2020; 48: 1103-1110

      Linked Article